Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viatris Inc.

8.81
+0.07000.80%
Post-market: 8.79-0.0200-0.23%17:08 EDT
Volume:6.73M
Turnover:59.14M
Market Cap:10.34B
PE:-2.77
High:8.87
Open:8.72
Low:8.63
Close:8.74
Loading ...

Viatris Unveils Promising Phase 3 Data on Fast-Acting Meloxicam for Acute Surgical Pain at PAINWeek 2025

Reuters
·
Yesterday

Viatris Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Yesterday

Idorsia H1 Net Income CHF 52 Million

Reuters
·
30 Jul

Idorsia Ltd. Publishes Investor Presentation on Advancing Towards Profitability and Strategic Priorities

Reuters
·
30 Jul

Idorsia Ltd. Reports Significant Revenue Growth to CHF 130 Million and Reduced Non-GAAP Net Loss in H1 2025; EPS Improves to CHF (0.13)

Reuters
·
30 Jul

Viatris Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
29 Jul

The Trader: GM Is Loading Up on Its Own Shares. Investors Should Follow Suit. -- Barron's

Dow Jones
·
26 Jul

Viatris Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
23 Jul

Viatris Inc. Stock Falls 4.2%, Underperforms Market

Dow Jones
·
19 Jul

US FDA advisers vote against Otsuka's PTSD combination treatment

Reuters
·
19 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Independent Bank, Invesco

Reuters
·
19 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Eos Energy, Norfolk Southern, Coinbase

Reuters
·
19 Jul

Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday

MT Newswires Live
·
18 Jul

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target -- Barrons.com

Dow Jones
·
18 Jul

Viatris Fails to Meet Primary Endpoint of Phase 3 Study for Blepharitis Treatment

MT Newswires Live
·
18 Jul

Viatris eye therapy fails to meet late-stage trial goal

Reuters
·
18 Jul

Viatris Inc. Announces Positive Results from Phase 3 Trials of MR-142 and MR-141, and Provides Update on MR-139 Study for Blepharitis

Reuters
·
18 Jul

Viatris Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
17 Jul

Viatris (VTRS) Receives a Hold from Goldman Sachs

TIPRANKS
·
16 Jul

FDA staff raises efficacy concerns for Otsuka's PTSD combination drug

Reuters
·
16 Jul